IMMY - Imprimis Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.71
+0.02 (+1.18%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.69
Open1.69
Bid1.55 x 1900
Ask2.10 x 2000
Day's Range1.68 - 1.73
52 Week Range1.35 - 4.69
Volume118,763
Avg. Volume582,384
Market Cap35.116M
Beta1.33
PE Ratio (TTM)N/A
EPS (TTM)-0.84
Earnings DateNov 13, 2017 - Nov 17, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Trade prices are not sourced from all markets
  • Imprimis Pharmaceuticals Inc (IMMY): Has Recent Earnings Growth Beaten Long-Term Trend?
    Simply Wall St.17 days ago

    Imprimis Pharmaceuticals Inc (IMMY): Has Recent Earnings Growth Beaten Long-Term Trend?

    For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) track record on a high level, toRead More...

  • Associated Presslast month

    Imprimis reports 3Q loss

    The San Diego-based company said it had a loss of 28 cents per share. The pharmaceutical and drug compounding company posted revenue of $6.5 million in the period. The company's shares closed at $1.66. ...

  • Imprimis Pharmaceuticals Announces Third Quarter 2017 Results
    PR Newswirelast month

    Imprimis Pharmaceuticals Announces Third Quarter 2017 Results

    SAN DIEGO , Nov. 14, 2017 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today reported financial results for the third quarter 2017.  Third ...

  • ACCESSWIRElast month

    Investor Network Invites You to the Imprimis Pharmaceuticals Third Quarter 2017 Earnings Conference Call and Webcast Live on Tuesday, November 14, 2017

    SAN DIEGO, CA / ACCESSWIRE / November 13, 2017 / Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) will host a conference call and live webcast to discuss the results of the third quarter 2017, to be held ...

  • Capital Cubelast month

    ETFs with exposure to Imprimis Pharmaceuticals, Inc. : November 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Imprimis Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IMMY-US. Comparing the performance and risk of Imprimis Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Imprimis Pharmaceuticals to Host its Third Quarter 2017 Financial Report Conference Call and Webcast on November 14, 2017 at 4:15 p.m. EST
    PR Newswire2 months ago

    Imprimis Pharmaceuticals to Host its Third Quarter 2017 Financial Report Conference Call and Webcast on November 14, 2017 at 4:15 p.m. EST

    SAN DIEGO, Oct. 31, 2017 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced it will release third quarter 2017 financial results after the close of trading on Tuesday, November 14, 2017.  The company will host a conference call at 4:15 p.m. EST/1:15 p.m. PST on the same day to discuss the financial results and recent business developments. To participate in the call, please dial (877) 407-8035 for domestic callers or (201) 689-8035 for international callers.  To listen to the webcast, please click here or visit the investor relations section of the Imprimis website at www.ImprimisRx.com.  A dial in replay of the call will be available until December 14, 2017.  To access the replay, dial (877) 481-4010 domestically or (919) 882-2331 internationally and reference Replay ID: 22220.  The webcast replay will be available until February 14, 2018.

  • Imprimis Launches Surface Pharmaceuticals Subsidiary
    PR Newswire2 months ago

    Imprimis Launches Surface Pharmaceuticals Subsidiary

    SAN DIEGO, Oct. 24, 2017 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced it has filed a Form 8-K with the SEC which contains a corporate presentation for its subsidiary, Surface Pharmaceuticals, Inc.  The Surface presentation is also available at www.SurfacePharma.com. Surface Pharmaceuticals intends to advance state of the art treatments for ocular surface diseases by seeking FDA approval for three drug candidates for up to five indications.  Surface's drug candidates were formulated using technology covered by two issued patents and three pending patent applications.  Certain Surface drug formulations have been prescribed as compounded drugs and have demonstrated considerable anecdotal human clinical success.  The markets for Surface's drug candidates include dry eye disease and blepharitis, both of which exceed 1 billion dollars in annual U.S. pharmaceutical sales.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Stocks to Watch: Alcobra and Imprimis Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / October 20, 2017 / Alcobra headed higher on Thursday after the company's wholly-owned subsidiary Arcturus entered into a research collaboration and worldwide license agreement ...

  • Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis®
    PR Newswire2 months ago

    Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis®

    Dry Eye Disease is estimated to affect up to 30 million Americans and is commonly characterized by irritated, gritty, scratchy or burning eyes, blurred vision, and feeling particles in the eye when there are none. Advanced Dry Eye Disease may damage the front surface of the eye and ultimately impair vision.

  • What’s The Outlook For Loss-Making Imprimis Pharmaceuticals Inc (IMMY)?
    Simply Wall St.2 months ago

    What’s The Outlook For Loss-Making Imprimis Pharmaceuticals Inc (IMMY)?

    Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) continues its loss-making streak, announcing a -$13.47M earnings for its latest financial year ending. Since IMMY is currently burning more cash than it is making, it’sRead More...

  • Imprimis Pharmaceuticals Secures First Key Composition Patent for Dropless Therapy® Formulations
    PR Newswire2 months ago

    Imprimis Pharmaceuticals Secures First Key Composition Patent for Dropless Therapy® Formulations

    SAN DIEGO, Oct. 2, 2017 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced it has secured its first patent covering the company's innovative Dropless Therapy® formulations from the Australian Patent office, a division of IP Australia.  Patent 2014293665, "Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an anti-inflammatory agent" will expire March 27, 2034, not including any potential extensions.

  • Capital Cube3 months ago

    ETFs with exposure to Imprimis Pharmaceuticals, Inc. : September 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Imprimis Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IMMY-US. Comparing the performance and risk of Imprimis Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Imprimis Pharmaceuticals, Inc. :IMMY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017
    Capital Cube3 months ago

    Imprimis Pharmaceuticals, Inc. :IMMY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017

    Categories: Yahoo FinanceGet free summary analysis Imprimis Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Imprimis Pharmaceuticals, Inc. – Akorn, Inc., Antares Pharma, Inc., Retractable Technologies, Inc., Delcath Systems, Inc., ICU Medical, Inc. and Tandem Diabetes Care, Inc. (AKRX-US, ATRS-US, RVP-US, DCTH-US, ICUI-US ... Read more (Read more...)

  • FDA Curcumin Investigation Supports Imprimis Statement
    PR Newswire3 months ago

    FDA Curcumin Investigation Supports Imprimis Statement

    SAN DIEGO, Sept. 14, 2017 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, provided an update regarding the FDA MedWatch Notice issued on August 4, 2017. The FDA's letter dated September 5, 2017 to Imprimis Pharmaceuticals, states "non-pharmaceutical grade PEG 40 Castor Oil was used due to a mislabeling by the supplier."  This statement is consistent with Imprimis' previous statements in its press release on August 7, 2017. The company also confirms that upon discovery of the supplier's mislabeling, it immediately terminated its business relationship with the supplier. Mark L. Baum, CEO of Imprimis commented, "We are grateful for FDA's diligence in investigating this unfortunate incident.

  • Imprimis Releases Statement Regarding Allergan Lawsuit
    PR Newswire3 months ago

    Imprimis Releases Statement Regarding Allergan Lawsuit

    "Imprimis will aggressively defend itself against Allergan's frivolous lawsuit and will take action against Allergan to protect its good name, never yielding to Allergan's tactics to limit patient choice and drive up the cost of ophthalmic therapies to Americans.

  • Associated Press4 months ago

    Imprimis posts 2Q profit

    On a per-share basis, the San Diego-based company said it had net income of 6 cents. The pharmaceutical and drug compounding company posted revenue of $6.9 million in the period. In the final minutes of ...

  • Imprimis Pharmaceuticals Announces Second Quarter 2017 Financial Results
    PR Newswire4 months ago

    Imprimis Pharmaceuticals Announces Second Quarter 2017 Financial Results

    SAN DIEGO , Aug. 10, 2017 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today reported financial results for the second quarter 2017.  ...

  • ACCESSWIRE4 months ago

    Investor Network: Imprimis Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 10, 2017 / Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ) will be discussing their earnings results in their Q2 Earnings Call to be held on Thursday, August 10, 2017 ...

  • ACCESSWIRE4 months ago

    Investor Network Invites You to the Imprimis Pharmaceuticals Second Quarter 2017 Earnings Conference Call and Webcast Live on Thursday, August 10, 2017

    SAN DIEGO, CA / ACCESSWIRE / August 9, 2017 / Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) will host a conference call and live webcast to discuss the results of the second quarter 2017, to be held Thursday, ...

  • Imprimis Statement Regarding Curcumin Emulsion FDA MedWatch Notice
    PR Newswire4 months ago

    Imprimis Statement Regarding Curcumin Emulsion FDA MedWatch Notice

    Mark L. Baum, CEO of Imprimis stated, "Imprimis is 100% dedicated to patient safety and regulatory compliance. Imprimis has been successful because we place patient safety and compassion for those we serve above all else.

  • Forbes4 months ago

    FDA Links Naturopathic Turmeric Death To Contaminated Product

    A curcumin emulsion for injection made by compounding pharmacy ImprimisRx contained a dangerous impurity. The company formulates a variety of questionable products for intravenous use and pays a popular naturopathic doctor as a consultant.

  • Imprimis Pharmaceuticals to Host its Second Quarter 2017 Financial Report Conference Call and Webcast on August 10, 2017 at 4:15 p.m. EDT
    PR Newswire5 months ago

    Imprimis Pharmaceuticals to Host its Second Quarter 2017 Financial Report Conference Call and Webcast on August 10, 2017 at 4:15 p.m. EDT

    SAN DIEGO, July 31, 2017 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today reported it will release second quarter 2017 financial results after the close of trading on Thursday, August 10, 2017.  The company will host a conference call at 4:15 p.m. EDT/1:15 p.m. PDT on the same day to discuss the financial results and recent business developments. To participate in the call, please dial (877)-407-8035 for domestic callers or (201)-689-8035 for international callers.  To listen to the webcast, please click here or visit the investor relations section of the Imprimis website at www.ImprimisRx.com.  A dial in replay of the call will be available until September 10, 2017.  To access the replay, dial (877)-481-4010 domestically or (919)-882-2331 internationally and reference Replay ID: 18435.  The webcast replay will be available until November 10, 2017.

  • Imprimis Pharmaceuticals Patent-Pending Dropless and LessDrops Formulations Exceed One Million Patient Eyes Milestone
    PR Newswire5 months ago

    Imprimis Pharmaceuticals Patent-Pending Dropless and LessDrops Formulations Exceed One Million Patient Eyes Milestone

    Medications dispensed from Imprimis' FDA-registered outsourcing facility have provided patients and physicians with innovative high-quality solutions for ocular surgery recovery SAN DIEGO , July 27, 2017 ...

  • Imprimis Pharmaceuticals Announces $16 Million Debt Facility with SWK Holdings
    PR Newswire5 months ago

    Imprimis Pharmaceuticals Announces $16 Million Debt Facility with SWK Holdings

    SAN DIEGO, July 20, 2017 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced it has entered into a $16 million senior secured non-dilutive term loan agreement with SWK Funding LLC and its partners. SWK Funding LLC is a subsidiary of SWK Holdings Corporation, a healthcare focused investment firm.

  • PR Newswire6 months ago

    Imprimis Pharmaceuticals Sells Pennsylvania Facility and Sinus Assets

    Imprimis to focus resources on rapidly-growing core ophthalmology business SAN DIEGO , June 29, 2017 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical ...